glycogen synthase kinase 3 beta | News Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

43,438 results for “glycogen synthase kinase 3 beta”

Elraglusib Shows Promise for Advanced Salivary Gland Carcinoma in Upcoming AACR Presentation

Actuate Therapeutics and Lantern Pharma Collaborate on AI-Driven Elraglusib Development

Actuate Therapeutics Raises $17.25 Million to Advance GSK-3β Inhibitor for Difficult-to-Treat Cancers

Elraglusib Receives FDA Orphan Drug Designation for Soft Tissue Sarcoma

Elraglusib Receives FDA Rare Pediatric Disease Designation for Ewing Sarcoma

Elraglusib Granted FDA Rare Pediatric Disease Designation for Ewing Sarcoma

Elraglusib Receives FDA Orphan Drug Designation for Pancreatic Cancer Treatment

Elraglusib Receives EMA Orphan Drug Designation for Pancreatic Cancer Treatment

Integrated Machine Learning and Molecular Dynamics Framework Identifies Novel GSK-3β Inhibitor Candidates for Alzheimer's Disease

AMO Pharma Launches Largest-Ever Clinical Trial for Rare Heart Condition ARVC with GSK3β Inhibitor AMO-02

Page 1 of 1400